Hangzhou and Shaoxing, China, November 8, 2023 /PRNewswire/ — Ascletis Pharmaceuticals Limited (HKEX: 1672, “Ascletis”) announced today, Wu JinziThe founder, chairman and CEO of Ascletis was invited to attend the 10th International Symposium on the Cure of Hepatitis B in 2023 and deliver a speech boston, USA.
Dr. Wu was invited to participate in sub-forum 3: Clinical Immunology and Immunotherapy Updatea lecture titled “Efficacy and Safety of Monoclonal Antibodies Targeting PD-L1.”
Ascletis recently announced positive interim data from a Phase IIb expansion cohort of the subcutaneous PD-L1 antibody ASC22 (Envafolimab) for functional cure of chronic hepatitis B. The interim analysis included 25 patients who completed 24 weeks of treatment (19 patients in the ASC22 cohort and 6 patients in the placebo cohort). Topline results showed that in the ASC22 cohort, 4 patients (4/19, 21.1%) achieved HBsAg loss at the end of 24 weeks of treatment. In contrast, no patients in the placebo group (0/6, 0%) achieved HBsAg loss at the end of 24 weeks of treatment. ASC22 was generally safe and well tolerated. Most ASC22 drug-related adverse reactions were grade 1 or 2.
Representatives from Roche, GlaxoSmithKline, Gilead, Immunocore, VIR, Arbutus, Aligos and other companies as well as experts from the National Institutes of Health and universities Oxford, Massachusetts general Hospital, Johns Hopkins UniversityUniversity of Lyon 1, Hong Kong universityToronto Liver Disease Centre, Emory University Harvard Center for AIDS Research Northwestern University School of Medicine,University Milan Also attended the meeting. Ascletis was the only Chinese biotech company to attend the conference.
Chronic hepatitis B remains a significant unmet medical need globally, with approximately 86 million people living with chronic hepatitis B. China 1.59 million people in the United States are infected with hepatitis B virus (HBV) (1).
“It is an honor to be invited to participate in the 10th International Symposium on Hepatitis B Cure in 2023 and share our latest progress in developing immune checkpoint inhibitors for functional cure of chronic hepatitis B with the global industry. ASC22 is a global The most advanced clinical stage immunotherapy achieves functional cure of CHB by blocking the PD-1/PD-L1 pathway, that is, HBsAg disappears, and the number of patients with HBsAg ≤ 100 IU/mL is huge, accounting for approximately 15%-22% of the total number of patients. (twenty three). We will continue to accelerate clinical research on ASC22 to benefit CHB patients. ” Wu Jinzifounder, chairman and CEO of Ascletis.
|
(1)Lim JK, Nguyen MH, Kim WR, et al. Prevalence of chronic hepatitis B virus infection in the United States (J). American Journal of Gastroenterology 2020, 115(9): 1429-38. |
|
(2) Xie Y., Li Ming, Ou X. et al. HBeAg-positive patients with HBsAg < 100 IU/mL and HBV RNA negative are at lower risk for virologic relapse after discontinuation of nucleos
Source link
|